HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

VL-2397

a systemic antifungal agent

Also Known As:

ASP-2397; ASP2397

Networked: 6 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - VL-2397: 6
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - VL-2397: 6
Inorganic Chemicals: 9
- Coordination Complexes: 576
  - VL-2397: 6
Organic Chemicals: 133
- Coordination Complexes: 576
  - VL-2397: 6

Experts

1.	Nakamura, Ikuko: 2 articles (10/2019 - 01/2017)
2.	Aguiar, Mario: 1 article (09/2021)
3.	Dietl, Anna-Maria: 1 article (09/2021)
4.	Gsaller, Fabio: 1 article (09/2021)
5.	Haas, Hubertus: 1 article (09/2021)
6.	Misslinger, Matthias: 1 article (09/2021)
7.	Orasch, Thomas: 1 article (09/2021)
8.	Armas, Danielle: 1 article (11/2019)
9.	Fisher, Cindy L: 1 article (11/2019)
10.	Hopkins, Andrew M: 1 article (11/2019)

Related Diseases

1.	Aspergillosis 11/01/2019 - "The safety profile, consistent PK, and lack of drug accumulation support further development of VL-2397 in patients with invasive aspergillosis." 08/27/2022 - "GR-2397 (previously VL-2397, ASP2397) is a first-in-class antifungal agent for the treatment of invasive aspergillosis. "
2.	Disease Progression 10/01/2019 - "Histopathological investigation of lungs also showed that ASP2397 markedly suppressed disease progression. "
3.	Mycoses (Diseases, Fungus) 09/16/2021 - "Siderophore-mediated acquisition of iron has been shown to be indispensable for the virulence of several fungal pathogens, the siderophore transporter Sit1 was found to mediate uptake of the novel antifungal drug VL-2397, and siderophores were shown to be useful as biomarkers as well as for imaging of fungal infections. "
4.	Infections 01/01/2017 - "Discovery of a new antifungal agent ASP2397 using a silkworm model of Aspergillus fumigatus infection."
5.	Invasive Fungal Infections 01/01/2017 - "We further discuss the unmet clinical needs in the antifungal research field; efforts in reformulation of available drugs such as Amphotericin B nanoparticles for oral drug delivery; development of new agents of known antifungal drug classes, such as albaconazole, SCY-078, and biafungin; and new drugs with novel targets for treatment of invasive fungal infections, including nikkomycin Z, sordarin derivatives, VT-1161 and VT-1129, F901318, VL-2397, and T-2307."

Related Drugs and Biologics

1.	Antifungal Agents
2.	Siderophores
3.	Biomarkers (Surrogate Marker)
4.	Iron
5.	Amphotericin B (Amphotericin)
6.	T-2307
7.	ibrexafungerp
8.	albaconazole
9.	nikkomycin
10.	sordarin